■胶质母细胞瘤(GBM)是中枢神经系统(CNS)常见的恶性肿瘤之一,以快速增殖为特征,异质性,侵略性,手术后复发的倾向,预后不良。越来越多的证据表明,肿瘤发生与免疫逃逸有着千丝万缕的联系,而免疫治疗无疑是GBM临床治疗方案的重要补充,并将成为GBM治疗研究的重点和热点。本研究的目的是可视化和分析GBM免疫治疗的科学结果和研究趋势。
■从WebofScienceCoreCollection(WOScc)数据库检索有关GBM免疫治疗的出版物。主要使用CiteSpace和R软件进行文献计量和可视化分析,和国家/地区的文献计量在线分析平台(https://bibliometric.com/app),作者,期刊,与该领域出版物相关的参考文献和关键词。
■在该领域检索到的总共3491种出版物中,根据筛选标准,最终获得了1613份出版物,包括1007篇(62.43%)和606篇评论(37.57%)。出版物数量逐年增加,平均增长率(AGR)为17.41%。这个数字是美国最大的(717,44.45%),其次是中国(283,17.55%),美国表现出最强的国际合作。在研究机构中,杜克大学(94,5.83%)是该领域最大的出版商,其次是哈佛医学院(70,4.34%)。此外,该领域最多产的作者是OHNHSampson(51)和MICHAELLIM(43),作者之间的合作程度(DC)为98.26%。在共同引用的作者中,STUPPR(805)是被引用最多的作者,其次是REARDONDA(448)。发表出版物最多的杂志是《免疫学前沿》(75),在共同引用方面被引用最多的期刊是CLINCANCERRES(1322),其次是癌症(1230)。高频关键词包括胶质母细胞瘤(672)和免疫治疗(377)。在关键词共生分析的基础上进行聚类分析,产生17个簇,在此基础上,总结了GBM免疫治疗领域的研究现状和未来趋势。
■免疫治疗是目前备受关注的GBM新型治疗策略。在未来,有必要加强国家和机构之间在相关研究方面的合作与交流,以促进这一领域的发展。免疫疗法有望成为未来GBM治疗策略的重要组成部分。已经成为当前研究的热点,也将是未来研究的重点。
UNASSIGNED: Glioblastoma (GBM) is one of the common malignant tumors of the central nervous system (CNS), characterized by rapid proliferation, heterogeneity, aggressiveness, proneness to recurrence after surgery, and poor prognosis. There is increasing evidence that tumorigenesis is inextricably linked to immune escape, and immunotherapy is undoubtedly an important complement to clinical treatment options for GBM, and will be a focus and hot topic in GBM treatment research. The purpose of this study was to visualize and analyze the scientific results and research trends of immunotherapy for GBM.
UNASSIGNED: Publications concerning immunotherapy for GBM were retrieved from the Web of Science Core Collection (WOScc) database. Bibliometric and visual analysis was performed mainly using CiteSpace and R software, and the Online Analysis Platform of Literature Metrology (https://bibliometric.com/app) for countries/regions, authors, journals, references and keywords related to publications in the field.
UNASSIGNED: Among totally 3491 publications retrieved in this field, 1613 publications were finally obtained according to the screening criteria, including 1007 articles (62.43%) and 606 reviews (37.57%). The number of publications increased year by year, with an average growth rate (AGR) of 17.41%. Such a number was the largest in the USA (717, 44.45%), followed by China (283, 17.55%), and the USA showed the strongest international collaboration. Among the research institutions, Duke Univ (94, 5.83%) was the largest publisher in the field, followed by Harvard Med Sch (70, 4.34%). In addition, the most prolific authors in this field were OHN H SAMPSON (51) and MICHAEL LIM (43), and the degree of collaboration (DC) between authors was 98.26%. Among the co-cited authors, STUPP R (805) was the most cited author, followed by REARDON DA (448). The journal with the most published publications was FRONTIERS IN IMMUNOLOGY (75), and the most cited journal in terms of co-citation was CLIN CANCER RES (1322), followed by CANCER RES (1230). The high-frequency keyword included glioblastoma (672) and immunotherapy (377). Cluster analysis was performed on the basis of keyword co-occurrence analysis, yielding 17 clusters, based on which the current research status and future trends in the field of immunotherapy for GBM were identified.
UNASSIGNED: Immunotherapy is currently a novel treatment strategy for GBM that has attracted much attention. In the future, it is necessary to strengthen cooperation and exchanges between countries and institutions towards relevant research to promote the development of this field. Immunotherapy is expected to be an important part of the future treatment strategy for GBM, and it has already become a hot spot of current research and will be the key focus of future research.